[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Gordon Schanzlin New Vision\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100650291","phase-4-the-effectiveness-of-systane-pro-preservative-free-verses-blink-triple-care-preservative-free-100650291",false,"NCT07745062","The Effectiveness of Systane PRO Preservative Free Verses Blink Triple Care Preservative Free","The Effectiveness of Systane PRO Preservative Free Verses Blink Triple Care Preservative Free in Providing Relief From Multiple Symptoms of Dry Eye Disease, and Its Impact on Daily Functioning and Overall Comfort in Dry Eye Subjects","SYSTANEvBLINK","Inclusion Criteria:\n\n* Age: Adults ≥ 18 years.\n* Diagnosis: Clinical diagnosis of mild to moderate dry eye disease in at least one eye with OSDI ≥ 13 to ≤ 32 at screening.\n* OSDI ≥ 13 to ≤ 32 at screening.\n* Objective evidence: NITBUT ≤ 10 seconds in the study eye(s) at screening.\n* Ocular surface status: CFS ≤ grade 3 (Oxford or NEI scale) in the study eye(s).\n* Stable medications: Systemic medications that may affect tear film must be stable ≥ 30 days prior to screening and expected to remain stable during the study.\n* Ability to participate: Able and willing to comply with procedures, attend visits, and provide written informed consent.\n* Contraception: Women of childbearing potential must agree to use an acceptable method of contraception for the study duration and have a negative pregnancy test at screening.\n\nExclusion Criteria:\n\n* Active ocular infection or inflammation unrelated to DED (e.g., bacterial\u002Fviral conjunctivitis, active uveitis).\n* Severe ocular surface disease beyond typical DED (e.g., severe keratitis, Stevens-Johnson syndrome, ocular cicatricial pemphigoid).\n* Excessive corneal staining: CFS \\> grade 3 in the study eye(s).\n* Recent ocular surgery or procedure: ocular surgery, laser, or punctal occlusion within 6 months prior to screening.\n* Current or prior use within 6 months before screening of either study drop (Systane PRO PF or Blink Triple Care PF)\n* Contact lens wear: soft or rigid contact lens use within 7 days prior to baseline, or unwillingness to discontinue lenses for the study; consider extending to 14 days if desired.\n* Use of topical ophthalmic medications that cannot be discontinued (e.g., topical antibiotics, corticosteroids).\n* Recent investigational product use: participation in another interventional trial or investigational product use within 30 days prior to screening.\n* Known hypersensitivity: allergy to any component of Systane PRO PF or Blink Triple Care PF.\n* Confounding systemic conditions: systemic diseases or medications that, in the investigator's judgment, could significantly affect tear production or ocular surface health (e.g., uncontrolled autoimmune disease, recent initiation\u002Fchange of systemic medications known to affect tear production within 30 days).\n* Severe visual impairment in the study eye(s) not attributable to DED that would interfere with assessments.\n* Pregnancy or breastfeeding.\n* Investigator discretion: any medical, psychiatric, or social condition that would preclude safe participation or reliable completion of study procedures.","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this investigational study is to determine if Systane PRO Preservative Free is non-inferior to BLINK TRIPLE CARE in the clinically significant improvement of signs and symptoms of dry eye in patients over 4 weeks.",[27],"Dry Eye Disease (DED)",[29],"Dry eye disease","RECRUITING","2026-07-29",{"date":33,"type":34},"2026-08-04","ACTUAL",{"date":36,"type":34},"2026-07-17",{"date":38,"type":21},"2027-04-01",{"name":40,"class":41},"Gordon Schanzlin New Vision","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":42},"100643061","refitting-satisfied-infuse-one-day-multifocal-wearers-to-dailies-total1-multifocal-contact-lenses-100643061","NCT07638943","Refitting Satisfied INFUSE One-Day Multifocal Wearers to DAILIES TOTAL1 Multifocal Contact Lenses","Clinical Outcomes Following Refit From INFUSE One-Day Multifocal to DAILIES TOTAL1 Multifocal in Satisfied Presbyopic Wearers: A Prospective, Open-Label, Single-Arm Study","INFUSETODT1","Inclusion Criteria:\n\nAge ≥40 years at enrollment Current satisfied wearer of Bausch + Lomb INFUSE One-Day Multifocal (kalifilcon A) in both eyes; Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) score \\\u003C12 at baseline Minimum contact lens wear of ≥8 hours\u002Fday, ≥5 days\u002Fweek, for ≥30 days prior to Visit 1 Best-corrected distance visual acuity ≥20\u002F25 (0.18 LogMAR) or better in each eye Manifest refraction within study lens parameters (Sphere: +6.00 D to -10.00 D; Add: Low, Medium, High) Willing to wear DAILIES TOTAL1 Multifocal lenses for ≥8 hours\u002Fday, ≥5 days\u002Fweek and complete all study questionnaires Able to provide written informed consent and comply with investigator instructions\n\nExclusion Criteria:\n\nActive ocular infection, inflammation, or clinically significant ocular surface disease (e.g., severe dry eye, pterygium, keratoconus) Uncontrolled systemic disease or use of systemic medications known to significantly affect the tear film, unless on a stable dose for ≥90 days History of refractive surgery (LASIK, PRK, RK) or intraocular surgery (cataract or IOL implantation) Clinically significant ectropion, entropion, or trichiasis Baseline corneal fluorescein staining score \\>2 in any single zone (NEI\u002FIndustry scale) Current monovision or modified monovision contact lens wear Pregnant or lactating participants Participation in another clinical trial within 30 days prior to enrollment",true,"40 Years",{"count":20,"type":21},[55],"NA","The purpose of this study is to determine the comfort and vision of DAILIES TOTAL1 Multifocal contact lenses in a population of satisfied INFUSE One-Day Multifocal contact lens wearers",[58,59],"Contact Lens Comfort and Successful Refitting","Presbyopia",[61],"contact lenses","2026-06-09",{"date":64,"type":34},"2026-06-11",{"date":66,"type":34},"2026-05-20",{"date":68,"type":21},"2027-02-28",{"name":40,"class":41},""]